Medications are nutrition. That’s essentially the rationale behind a couple of Big Pharma corporations’ decision to give a failed Alzheimer’s drug a second chance.
In early August, Pfizer and Johnson & Johnson said they were ending large-scale clinical trials of their experimental drug bapineuzumab in patients with mild to moderate Alzheimer’s disease, because patients taking it did not show signs of improved memory or thinking skills.
That was disappointing to millions of Alzheimer’s sufferers and their families, though the results of the trials were all but expected by researchers and investors who believed the drug had little chance to succeed.
Post Continues on www.naturalnews.com